Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer
This study is currently recruiting participants.
Verified September 2012 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Memorial Sloan-Kettering Cancer Center
Collaborator:
Memorial University Medical Center
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00588029
First received: December 24, 2007
Last updated: September 7, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121019031544im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of this study is to collect a blood sample from patients with breast disease (cases) and from individuals without breast cancer (controls)that may be used for research purposes. These blood samples will be used by researchers at Memorial Sloan-Kettering Cancer Center who study the causes of breast cancer, as well as more effective ways to prevent, diagnose, and treat breast cancer.
Condition |
---|
Breast Cancer |
Study Type: | Observational |
Study Design: | Observational Model: Case Control Time Perspective: Prospective |
Official Title: | Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer |
Resource links provided by NLM:
Further study details as provided by Memorial Sloan-Kettering Cancer Center:
Primary Outcome Measures:
- None. This is a tissue banking study. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood, Cerebro-Spinal Fluid and Saliva
Estimated Enrollment: | 7000 |
Study Start Date: | July 1999 |
Estimated Study Completion Date: | December 2013 |
Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
breast cancer patients
|
2
control subjects without breast cancer
|
![](https://webarchive.library.unt.edu/web/20121019031544im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Study Population
Breast cancer patients seen at Memorial Sloan-Kettering Cancer Center
Criteria
Inclusion Criteria:
- For acquisition of existing breast cancer tissue specimens from the MSKCC Tissue Procurement Service, the only criteria are a pathologically-confirmed diagnosis of invasive breast cancer and the availability of corresponding nonmalignant tissue from each case.
- For the prospective acquisition of blood or saliva from control subjects without breast cancer, eligibility criteria include:
- Any patient with a previous diagnosis of invasive breast cancer who undergoes a palliative procedure related to the presence of a pleural effusion is eligible for the pleural fluid collection aspect of this protocol.
- Any female patient, or any female over the age of 18 accompanying a patient under the care of a physician in the Department of Urology, Department of Surgery, or Department of Medicine.
- Subjects will have no history of preinvasive (carcinoma in situ) or invasive breast cancer.
- Subjects will be eligible without regard to racial, or ethnic status. Attending physicians authorized to obtain informed consent may exercise discretion in excluding individuals for appropriate medical or other (e.g., mentally impaired) reasons.
- For the prospective acquisition of blood, saliva, pleural fluid or cerebrospinal fluid from patients who have or are suspected of having breast cancer or carcinoma in-situ, eligibility criteria include:
- Any patient at MSKCC with a previously confirmed or suspected diagnosis of malignant or premalignant (e.g., carcinoma in situ) breast disease is eligible for inclusion in the blood acquisition aspect of this protocol.
- Any patient with a previous diagnosis of invasive breast cancer who undergoes a palliative procedure related to the presence of a pleural effusion is eligible for the pleural fluid collection aspect of this protocol.
- Any patient with a previous diagnosis of invasive breast cancer with leptomeningeal metastasis who undergoes a routine procedure associated with the collection of cerebrospinal fluid is eligible for the cerebrospinal fluid collection aspect of this protocol.
- All subjects must be under the care of one or more members of the MSKCC Breast Disease Management Team at the time of enrollment.
- Subjects may have received prior hormonal therapy, cytotoxic chemotherapy, radiation therapy, or surgical therapy at MSKCC or another institution.
- All subjects must be 18 years or older
- Subjects will be eligible without regard to sex, racial, or ethnic status. It is anticipated that approximately 99% of the patients will be female. Attending physicians authorized to obtain informed consent may exercise discretion in excluding individuals for appropriate medical or other (e.g., mentally impaired) reasons.
- If, after pathologic diagnosis, preinvasive or invasive breast disease is not found, patients previously consented for the blood collection aspect of this protocol will not be included.
Exclusion Criteria:
For the prospective acquisition of blood or saliva from control subjects without breast cancer, ineligibility criteria include:
- A first degree relative (mother, daughter, sister, father, brother or son) who has been diagnosed with breast cancer.
- A personal history of breast cancer, lobular carcinoma in situ or atypia.
![](https://webarchive.library.unt.edu/web/20121019031544im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00588029
Contacts
Contact: Tari King, MD | 646-888-5352 | |
Contact: Mark Robson, MD | 646-888-4058 |
Locations
United States, New York | |
Memorial Sloan-Kettering Cancer | Recruiting |
New York, New York, United States, 10065 | |
Contact: Tari King, MD 646-888-5352 | |
Contact: Mark Robson, MD 646-888-4058 | |
Principal Investigator: Tari King, MD |
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Memorial University Medical Center
Investigators
Principal Investigator: | Tari King, MD | Memorial Sloan-Kettering Cancer Center |
![](https://webarchive.library.unt.edu/web/20121019031544im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | Memorial Sloan-Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00588029 History of Changes |
Other Study ID Numbers: | 99-030 |
Study First Received: | December 24, 2007 |
Last Updated: | September 7, 2012 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
Family members |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on October 17, 2012